Ernst and Young round table identifies new investors
This article was originally published in Clinica
Executive Summary
There is a new type of investor in the biotech industry, according to a panel assembled as part of the 12th Annual Biotechnology Industry Report, published by the global accountancy company, Ernst & Young. There are those, particularly in Europe, who are following a trend set in the early 1990s in the US, by investing solely in the sector. Others have made an investment calculation based on the results of clinical trials, despite the fact that those trials may not be favourable to the companies concerned.
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.